S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Spero Therapeutics (SPRO) Stock Forecast, Price & News

+0.04 (+3.33%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
451,947 shs
Average Volume
473,501 shs
Market Capitalization
$40.70 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Spero Therapeutics logo

About Spero Therapeutics

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.


Spero Therapeutics (NASDAQ:SPRO) PT Lowered to $10.00
Where Spero Therapeutics Stands With Analysts
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$18.26 million
Book Value
$1.90 per share


Net Income
$-89.76 million
Net Margins
Pretax Margin




Free Float
Market Cap
$40.70 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.63 out of 5 stars

Medical Sector

77th out of 1,424 stocks

Pharmaceutical Preparations Industry

28th out of 681 stocks

Analyst Opinion: 3.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.3 5 -4 -3 -2 -1 -

Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

Is Spero Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Spero Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares.
View analyst ratings for Spero Therapeutics
or view top-rated stocks.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,650,000 shares, a decline of 55.3% from the April 30th total of 3,690,000 shares. Based on an average daily trading volume, of 634,900 shares, the days-to-cover ratio is currently 2.6 days. Approximately 6.8% of the company's shares are sold short.
View Spero Therapeutics' Short Interest

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Spero Therapeutics

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its earnings results on Monday, May, 16th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.87) by $0.14. Spero Therapeutics had a negative trailing twelve-month return on equity of 116.93% and a negative net margin of 792.03%. During the same period last year, the company posted ($0.66) EPS.
View Spero Therapeutics' earnings history

What price target have analysts set for SPRO?

5 Wall Street analysts have issued 1-year price objectives for Spero Therapeutics' shares. Their forecasts range from $5.00 to $70.00. On average, they anticipate Spero Therapeutics' share price to reach $28.33 in the next twelve months. This suggests a possible upside of 2,184.9% from the stock's current price.
View analysts' price targets for Spero Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the following people:
  • Dr. Ankit Mahadevia M.D., MBA, Co-Founder, Pres, CEO & Director (Age 41, Pay $924.28k) (LinkedIn Profile)
  • Mr. Satyavrat Shukla C.F.A., CFO & Treasurer (Age 50, Pay $788.84k)
  • Ms. Cristina Larkin, Chief Operating Officer (Age 52, Pay $654.95k)
  • Dr. Thomas R. Parr Jr., Ph.D., Chief Scientific Officer (Age 68)
  • Ted Jenkins, VP & Head of Investor Relations
  • Ms. Tamara Lynn Joseph L.L.M., Chief Legal Officer (Age 59)
  • Mr. David Musselman, Sr. VP of Sales & Market Access
  • Mr. James P. Brady, Chief Human Resource Officer
  • Mr. Timothy Keutzer, Chief Devel. Officer (Age 54)
  • Dr. David A. Melnick M.D., Chief Medical Officer (Age 70)
What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.19%), Rock Springs Capital Management LP (3.02%), State Street Corp (1.52%), Dimensional Fund Advisors LP (1.24%), Northern Trust Corp (0.73%) and Royal Bank of Canada (0.60%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics

Which major investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Granahan Investment Management LLC, Williams Jones Wealth Management LLC., New York State Common Retirement Fund, JPMorgan Chase & Co., Northern Trust Corp, and Group One Trading L.P..
View insider buying and selling activity for Spero Therapeutics
or view top insider-selling stocks.

Which major investors are buying Spero Therapeutics stock?

SPRO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eversept Partners LP, Rock Springs Capital Management LP, Walleye Capital LLC, Walleye Capital LLC, Dimensional Fund Advisors LP, GSA Capital Partners LLP, and Assenagon Asset Management S.A..
View insider buying and selling activity for Spero Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.24.

How much money does Spero Therapeutics make?

Spero Therapeutics has a market capitalization of $40.70 million and generates $18.26 million in revenue each year. The company earns $-89.76 million in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Spero Therapeutics have?

Spero Therapeutics employs 146 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at (857) 242-1600 or via email at [email protected].

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.